Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose on day 1 through day 43
Summary
This trial tests a new drug, LY3473329, in healthy Japanese participants to see if it is safe and how the body handles it. Researchers will measure how quickly it enters the bloodstream and how long it stays in the body.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ predose on day 1 through day 43
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose on day 1 through day 43
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary study objectives
PK: Maximum Concentration (Cmax) of LY3473329
PK: Time to Maximum Concentration (Tmax) of LY3473329
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3473329
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3473329Experimental Treatment1 Intervention
LY3473329 administered orally.
Group II: PlaceboPlacebo Group1 Intervention
Placebo administered orally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3473329
2023
Completed Phase 2
~410
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,671 Previous Clinical Trials
3,228,998 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,386 Previous Clinical Trials
426,623 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger